# Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

> **NCT02132299** · PHASE1 · COMPLETED · sponsor: **Sanaria Inc.** · enrollment: 67 (actual)

## Conditions studied

- Malaria
- Plasmodium Falciparum Malaria

## Interventions

- **BIOLOGICAL:** PfSPZ Vaccine
- **BIOLOGICAL:** Normal Saline (Placebo)
- **BIOLOGICAL:** PfSPZ Challenge

## Key facts

- **NCT ID:** NCT02132299
- **Lead sponsor:** Sanaria Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-07
- **Final completion:** 2015-08
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2016-04-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132299, "Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02132299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*